We sought to conduct a systematic review to compare the long-term effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) when they are added to guideline-mediated therapy to treat patients with heart failure. This evidence concerns the gene SLC5A2 and heart failure.